Drug intelligence / Profile preview

NCP-01

Development stage: Preclinical
Lead developer: Hemostemix
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal, Intravenous

Overview

NCP-01 is an autologous neural cell precursor (NCP) therapy developed by Hemostemix and its subsidiary PreCerv. The therapy is derived from a patient's own peripheral blood using Hemostemix's proprietary automated cell manufacturing platform. NCP-01 is designed to treat conditions of the central and peripheral nervous system by providing a source of cells capable of differentiating into neural lineages and secreting neurotrophic factors to promote tissue repair and regeneration. Hemostemix granted a global field-of-use license to PreCerv to specifically advance the development of NCP-01 for neurological indications, including neurodegenerative diseases and nerve injuries.

Other names: Neural Cell Precursors

Beyond the preview

Go deeper on NCP-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCP-01.

Explore the full profile